Lv5
1550 积分 2022-06-14 加入
Efficacy of Tyrosine Kinase Inhibitors in Primary Driver-Gene-Positive Combined Small-Cell Lung Cancer: A Retrospective Study
16小时前
已完结
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR -Mutant Advanced Non–Small Cell Lung Cancer Treated with First-Line Osimertinib
2个月前
已完结
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
5个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
5个月前
已完结
Molecular heterogeneity in prostate cancer and the role of targeted therapy
6个月前
已完结
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
7个月前
已完结
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
8个月前
已完结
p53 at the crossroads of tumor immunity
11个月前
已完结
MDM2 inhibitors in sarcomas: results and next steps
1年前
已完结
Clear cell mesotheliomas with inactivating VHL mutations and near‐haploid genomic features
1年前
已完结
皖公网安备34019202002308
